A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Inclusion Criteria

• •The subject must have already received tremelimumab in another protocol
• •Females of childbearing potential must agree to practice a form of effective contraception for 12 months following any dose of study drug. The definition of effective contraception will be based on the judgement of the investigator.
• •Subject must be willing and able to provide written informed consent and to comply with scheduled visits and other trial procedures